Meilleur Technologies, Inc. announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).

November 6, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). 

The collaboration will involve the network of Alzheimer’s Disease Research Centers across the country (currently, there are 37 centers of excellence), will recruit 2000 subjects, and apply cutting-edge imaging and blood-based biomarkers to investigate the multiple intersecting neurodegenerative causes of cognitive impairment (known collectively as Alzheimer’s disease and related disorders or ADRD). 

Sterling Johnson, the CLARiTI STUDY Lead, stated: “A major gap in our field is the ability to detect and develop a temporal profile of the several pathologies that may be present in our older patients with cognitive symptoms. This requires a broad panel of biomarkers. The partnership with Meilleur will enable accessible state of the art amyloid PET imaging, which we believe is foundational to further discovery.” 

“Meilleur is focused on enabling access to key technologies such as NAV-4694, a highly sensitive molecular imaging tool, with the aim to better understand disease and ultimately support the acceleration of drug development in neurodegenerative disorders,” said Samantha Budd Haeberlein, Chief Medical Officer, Meilleur Technologies, Inc. “The NIA-sponsored CLARiTI study will provide critical data on early amyloid deposition across a large population with Alzheimer’s disease and related disorders. We applaud the NIA and the ADRC for their initiative.” 

For more information: 


Related Alzheimer's Content:      

Research Suggests Specialized Brain Imaging can Unveil Mysteries of Alzheimer’s Disease, Other Disorders      

FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm      

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease      

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients      

Good Results for Alzheimer’s Imaging Agent      

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers      

Alzheimer’s Association Launches New Website for IDEAS Study      

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment      

Impaired Glymphatic System May be Linked with Progression of Alzheimer's Disease, Finds New Study    

Radiologists Must Monitor Novel Alzheimer’s Treatment Side Effect  

Related Content

News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
Feature | PET-CT | By Melinda Taschetta-Millane

According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...

Time January 17, 2024
News | Prostate Cancer

January 5, 2024 — Perspective Therapeutics, Inc., announced that it has entered into a patent license agreement with ...

Time January 05, 2024
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
Subscribe Now